Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Aspen Pharmacare Holdings stock

APN.JO
ZAE000066692
A0ET80

Price

176.56
Today +/-
-858.37
Today %
-195.78 %

Aspen Pharmacare Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aspen Pharmacare Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aspen Pharmacare Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aspen Pharmacare Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aspen Pharmacare Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aspen Pharmacare Holdings Stock Price History

DateAspen Pharmacare Holdings Price
12/20/2024176.56 undefined
12/19/202416,547.00 undefined
12/18/202416,886.00 undefined
12/17/202416,667.41 undefined
12/13/202416,933.00 undefined
12/12/202416,912.00 undefined
12/11/202417,073.00 undefined
12/10/202416,805.00 undefined
12/9/202416,900.00 undefined
12/6/202416,878.00 undefined
12/5/202416,969.00 undefined
12/4/202417,194.00 undefined
12/3/202416,825.00 undefined
12/2/202416,988.00 undefined
11/29/202416,565.00 undefined
11/28/202416,599.00 undefined
11/27/202416,611.00 undefined
11/26/202416,802.00 undefined
11/25/202416,731.00 undefined
11/22/202417,007.00 undefined
11/21/202417,025.00 undefined

Aspen Pharmacare Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aspen Pharmacare Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aspen Pharmacare Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aspen Pharmacare Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aspen Pharmacare Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aspen Pharmacare Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aspen Pharmacare Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aspen Pharmacare Holdings’s growth potential.

Aspen Pharmacare Holdings Revenue, EBIT and net profit per share

DateAspen Pharmacare Holdings RevenueAspen Pharmacare Holdings EBITAspen Pharmacare Holdings Net Income
2027e56.51 B undefined13.58 B undefined10.32 B undefined
2026e53.07 B undefined12.73 B undefined9.51 B undefined
2025e48.63 B undefined11.12 B undefined8.16 B undefined
202444.71 B undefined8.89 B undefined4.4 B undefined
202340.71 B undefined8.89 B undefined5.23 B undefined
202238.61 B undefined9.86 B undefined6.49 B undefined
202137.77 B undefined7.84 B undefined4.81 B undefined
202033.66 B undefined7.18 B undefined4.66 B undefined
201935.51 B undefined8.75 B undefined6.46 B undefined
201838.31 B undefined9.76 B undefined6.04 B undefined
201741.2 B undefined9.6 B undefined5.1 B undefined
201635.6 B undefined10.2 B undefined4.3 B undefined
201536.13 B undefined8.64 B undefined5.2 B undefined
201429.52 B undefined7.53 B undefined5.01 B undefined
201319.31 B undefined5.11 B undefined3.52 B undefined
201215.26 B undefined3.94 B undefined2.82 B undefined
201112.38 B undefined3.15 B undefined2.58 B undefined
201010.15 B undefined2.62 B undefined1.99 B undefined
20098.45 B undefined2.18 B undefined1.34 B undefined
20084.88 B undefined1.23 B undefined863 M undefined
20074.03 B undefined1.08 B undefined717 M undefined
20063.45 B undefined895 M undefined638 M undefined
20052.87 B undefined758 M undefined494 M undefined

Aspen Pharmacare Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.120.521.211.151.581.92.22.873.454.034.888.4510.1512.3815.2619.3129.5236.1335.641.238.3135.5133.6637.7738.6140.7144.7148.6353.0756.51
-338.66131.03-4.7337.7720.0915.8330.2920.2216.7321.2473.1220.0822.0423.2026.5652.8622.40-1.4615.73-7.00-7.31-5.2212.202.225.459.828.779.136.49
-3.3646.9349.1752.5747.5045.2948.0548.5248.1348.2445.5445.9945.3745.3447.6947.8146.4947.7650.2848.3051.3852.3350.9147.1047.4246.5143.5240.0136.6634.43
-00.250.590.60.750.861.061.391.661.942.223.894.65.617.289.2313.7217.2517.919.919.6918.5817.1417.7918.3118.9319.45000
-0.020.060.110.180.230.270.360.490.640.720.861.341.992.582.823.525.015.24.35.16.046.464.664.816.495.234.48.169.5110.32
--361.9090.9169.5226.9719.9131.3738.7629.1512.3820.3655.2748.5129.559.3124.9142.273.85-17.3218.6018.377.06-27.843.0435.00-19.42-15.7685.2016.548.57
------------------------------
------------------------------
62291374382368368372358362362375383426454436456456456.45456.5456.4456.4456.5456.5456.5453444.2444.2000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Aspen Pharmacare Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aspen Pharmacare Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
0.010.120.140.140.180.20.470.450.643.331.542.082.943.043.316.020010.910.7111.178.987.098.556.1810.9112.34
0.020.290.140.220.290.350.340.450.620.760.991.491.892.563.834.11008.812.449.658.999.057.78.2410.0910.3
000.050.030.040.050.040.050.050.090.570.350.340.4600.7500103.23.113.832.744.043.543.2
0.010.240.170.190.290.210.250.430.80.941.451.442.042.633.294.10014.414.0114.9614.6516.4113.4115.7619.6118
000.0100.010.020.050.030.040.020.220.240.420.6800.80.411.062.10.20.520.430.350.310.340.360.25
0.040.640.510.570.820.831.141.392.155.144.765.67.629.3810.4315.780.411.0637.237.3639.4936.1536.7432.7134.5644.544.09
00.270.160.150.150.510.70.940.612.436.157.0410.2111.113.814.34009.79.7511.3712.0714.8315.2316.2218.920.51
0200149197377390377262320000.1116.32000249000000
0000000000.010.010.010.030.010.030.030.30.290.200.941.021.150.620.350.270.65
0000.140.290.110.060.050.82-0.73-0.68-0.571.411.4611.8718.930049.160.0172.1666.4773.0454.8853.6563.166.35
00.40.080.110.050.070.090.270.260.30.590.40.464.635.345.970065.946.134.655.384.625.015.65.46
0.0200.210.230.190.150.130.110.030.0200.020.070.220.230.37001.92.541.771.962.041.631.581.922.09
0.020.680.450.630.690.850.971.742.122.396.096.9212.1817.4221.2929.650.30.4167.178.2392.6186.1696.4376.9876.8189.7895.07
0.061.320.961.211.511.682.113.144.277.5310.8512.5219.826.831.7245.420.711.47104.3115.59132.11122.32133.17109.68111.38134.28139.16
                                                     
0.030.050.050.050.050.050.050.071.120.910.660.675.214.914.70.06002.11.932.092.092.092.092.022.022.02
00.210.20.180.240.170.140.410.190.270.46-0.170.060.0603.9900000000000
-0.01-0.100.190.40.640.951.271.031.812.713.685.768.412.6914.870028.531.6636.3941.345.9650.8254.4184.5783.21
000000000000-0.18-0.1103.930012.18.7811.0611.0121.3512.9314.7500
000000000000000000000000000
0.020.170.250.420.690.861.141.752.342.983.834.1810.8513.2617.3922.850042.742.3649.5354.3969.465.8471.1886.5885.23
0.010.490.190.280.360.340.350.60.710.410.540.71.091.212.932.23.593.433.510.264.493.933.373.33.643.974.37
0000000000.110.150.230.270.6301.141.831.972.603.843.294.014.985.475.45.31
000.120.10.110.120.130.130.070.320.440.620.751.230.261.38004.15.698.654.584.43.872.625.873.38
0000000000001.131.2902.6300303.062.831.482.591.213.425.12
0.010.520.120.20.160.150.290.761.173.85.762.672.593.854.135.52007.918.868.175.424.8322.0210.454.496.2
0.0210.430.580.640.610.771.491.964.636.894.225.838.217.3212.875.425.421.134.8128.220.0418.0836.7523.423.1524.38
00.370.280.180.050.150.160.410.450.430.483.832.654.636.258.92003528.9846.7339.7136.020.2710.5821.3825.14
0-0.2100.040.040.040.060.090.10.070.160.20.260.510.540.6001.82.092.212.052.71.811.9721.58
0000.070.150.090.050.030.030.020.010.010.180.170.210.23003.97.335.596.37.155.234.491.533.19
00.160.280.280.240.280.270.540.590.510.654.043.095.379.760040.738.454.5348.0645.877.3117.0424.929.91
0.021.160.710.860.870.891.042.032.545.147.538.268.9213.5114.3222.625.425.461.873.282.7368.163.9544.0640.4348.0554.29
0.041.320.961.271.561.752.193.784.888.1211.3612.4419.7626.7731.7145.485.425.4104.5115.57132.26122.49133.35109.9111.61134.63139.52
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aspen Pharmacare Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aspen Pharmacare Holdings's financial health and stability.

Assets

Aspen Pharmacare Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aspen Pharmacare Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aspen Pharmacare Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aspen Pharmacare Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-00.080.250.30.430.500.760.971.081.232.232.823.605.047.428.4598.39.265.067.067.078.677.82
00.010.030.020.020.0300.120.140.180.190.220.270.3600.550.821.041.21.31.371.271.61.641.711.79
00000000000000000000000000
-0.010.01-0.01-0.12-0.21-0.140.5-0.25-0.73-0.61-0.84-1.38-1.24-1.372.91-1.97-4.07-4.67-6.6-4.3-4.91-4.92-2.85-2.05-4.65-5.78
00-0.040-0.01000.010.020.060.070.220.18-0.1400.37-0.340.02-0.41.21.34.582.450.17-0.361.69
000000.070.030.080.090.190.350.760.610.590.510.880.992.3922.22.082.131.781.210.411.34
00.010.030.020.050.050.10.180.180.210.320.330.470.530.450.81.181.191.51.51.51.81.411.631.691.61
-0.010.110.230.210.230.390.50.640.40.710.651.292.032.452.913.993.844.843.26.57.0268.266.835.375.52
39-81-60-51-56-261-248-167-179-290-383-3,279-633-651-469-667-1,328-1,592-1,700-1,500-3,026-3,583-2,690-3,431-2,697-3,181
0.04-1.730.28-0.11-0.04-0.35-0.28-0.79-0.45-0.43-1.46-3.56-1.02-5.65-2.66-6.28-20.85-1.561.1-11.7-12.813.241.629.76-2.16-3.42
-0-1.650.34-0.060.02-0.09-0.03-0.63-0.27-0.14-1.07-0.28-0.39-4.99-2.19-5.62-19.520.032.8-10.2-9.796.824.3113.190.54-0.24
00000000000000000000000000
-0.020.86-0.48-0.03-0.160.080.160.25-0.010.141.443.11-0.483.570.144.3420.18-1.37-26.27.69-9.76-11.42-15.6-1.621.17
207050-7561013646332715202-105-11-19-22-1000-44-29-41-50-1,857-136
-01.57-0.48-0.11-0.20.020.050.12-0.15-0.051.213.13-0.53.25-0.293.6119.45-2.24-3.156.33-11.27-11.47-15.65-4.68-0.42
000-6-20-32-48-6730000-21-627104000-410000
0000-28-40-71-101-166-216-24700-304-459-715-716-857-1,000-1,200-1,313-1,43700-1,196-1,455
0.02-0.050.02-0.010.050.020.27-0.03-0.180.240.450.380.49-0.060.241.432.750.71-0.70.93-1.97-0.530.34-0.982.52
32.128.8171.1159.4177.7132.8250470.9223418.1269.4-1,987.71,4001,794.22,438.83,3192,507.43,2461,5005,0003,9912,4195,5703,3942,6772,339
00000000000000000000000000

Aspen Pharmacare Holdings stock margins

The Aspen Pharmacare Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aspen Pharmacare Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aspen Pharmacare Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aspen Pharmacare Holdings's sales revenue. A higher gross margin percentage indicates that the Aspen Pharmacare Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aspen Pharmacare Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aspen Pharmacare Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aspen Pharmacare Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aspen Pharmacare Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aspen Pharmacare Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aspen Pharmacare Holdings Margin History

Aspen Pharmacare Holdings Gross marginAspen Pharmacare Holdings Profit marginAspen Pharmacare Holdings EBIT marginAspen Pharmacare Holdings Profit margin
2027e43.52 %24.03 %18.26 %
2026e43.52 %24 %17.91 %
2025e43.52 %22.86 %16.77 %
202443.52 %19.89 %9.85 %
202346.51 %21.83 %12.84 %
202247.42 %25.54 %16.81 %
202147.1 %20.75 %12.73 %
202050.91 %21.32 %13.86 %
201952.33 %24.64 %18.2 %
201851.38 %25.48 %15.76 %
201748.3 %23.3 %12.38 %
201650.28 %28.65 %12.08 %
201547.76 %23.93 %14.4 %
201446.49 %25.51 %16.97 %
201347.81 %26.48 %18.23 %
201247.69 %25.83 %18.47 %
201145.34 %25.43 %20.82 %
201045.37 %25.77 %19.61 %
200945.99 %25.83 %15.86 %
200845.54 %25.24 %17.68 %
200748.24 %26.75 %17.81 %
200648.13 %25.95 %18.5 %
200548.52 %26.42 %17.22 %

Aspen Pharmacare Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Aspen Pharmacare Holdings earnings per share therefore indicates how much revenue Aspen Pharmacare Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aspen Pharmacare Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aspen Pharmacare Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aspen Pharmacare Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aspen Pharmacare Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aspen Pharmacare Holdings Revenue, EBIT and net profit per share

DateAspen Pharmacare Holdings Sales per ShareAspen Pharmacare Holdings EBIT per shareAspen Pharmacare Holdings Earnings per Share
2027e126.64 undefined0 undefined23.13 undefined
2026e118.91 undefined0 undefined21.3 undefined
2025e108.96 undefined0 undefined18.28 undefined
2024100.64 undefined20.02 undefined9.91 undefined
202391.65 undefined20 undefined11.77 undefined
202285.22 undefined21.76 undefined14.32 undefined
202182.73 undefined17.16 undefined10.53 undefined
202073.73 undefined15.72 undefined10.22 undefined
201977.8 undefined19.17 undefined14.16 undefined
201883.95 undefined21.39 undefined13.23 undefined
201790.27 undefined21.03 undefined11.17 undefined
201677.98 undefined22.34 undefined9.42 undefined
201579.15 undefined18.94 undefined11.4 undefined
201464.73 undefined16.51 undefined10.98 undefined
201342.34 undefined11.21 undefined7.72 undefined
201234.99 undefined9.04 undefined6.46 undefined
201127.28 undefined6.94 undefined5.68 undefined
201023.82 undefined6.14 undefined4.67 undefined
200922.06 undefined5.7 undefined3.5 undefined
200813.02 undefined3.29 undefined2.3 undefined
200711.12 undefined2.98 undefined1.98 undefined
20069.53 undefined2.47 undefined1.76 undefined
20058.01 undefined2.12 undefined1.38 undefined

Aspen Pharmacare Holdings business model

Aspen Pharmacare Holdings Ltd is a South African company that was founded in 1850 in Durban, South Africa. The company is now one of the largest manufacturers and suppliers of generic drugs in the world and employs over 10,000 people in 55 countries. The company's history dates back to its founder, William Waddell, who opened a pharmacy in Durban in 1850. Over the years, the pharmacy grew into a significant company in the region and expanded to other parts of South Africa in the 1930s. In 1997, the company was renamed Aspen Pharmacare Holdings and began focusing on the production of generic drugs. Aspen Pharma follows a diversified business model based on three pillars: generics, brands, and specialty pharmaceuticals. The company is one of the largest generic drug manufacturers in the world and offers a wide range of generics, including antibiotics, antidepressants, antidiabetics, and cardiovascular medications. The second pillar of the business model is the work in the branded pharmaceuticals sector. For this purpose, Aspen Pharmacare Holdings has a subsidiary called Aspen Global Incorporated, which is responsible for the development, approval, and marketing of patented drugs. Some of Aspen's most well-known branded products include Thrombophob, Emdocam, Bouchara-Recordati, and Zocor. The third pillar of the business model is the specialty pharmaceuticals segment. Here, the company offers medications for specific therapy areas such as cancer, multiple sclerosis, HIV/AIDS, and eye diseases. The company also has its own research and development department to develop and market new drugs. In recent years, Aspen Pharmacare Holdings has experienced impressive expansion. The company has conducted numerous acquisitions and mergers to increase its market presence and diversify its product range. An example of a significant acquisition by Aspen is the purchase of Australian company Sigma Pharmaceuticals in 2011. Through the acquisition of Sigma, Aspen was able to strengthen its role in the Australian market and improve its position in the global pharmaceutical market. In addition to manufacturing and selling drugs, the company also operates a range of other business areas. These include the production of medical devices, the development of medical technology, the manufacturing of biological drugs, and the provision of logistics and distribution services. The company is present in many third-world countries and aims to improve access to affordable medicines worldwide. Aspen has earned an excellent reputation as a pioneer in this field and has been actively involved in numerous projects and initiatives for years to improve healthcare in developing countries. In conclusion, Aspen Pharmacare Holdings is an impressive company with a long history and an extremely diverse product range. The company demonstrates strong growth dynamics while also advocating for improving public health and access to affordable medicines. Given the constantly changing healthcare industry and global threats posed by pandemics and other challenges, Aspen still has significant potential for growth, and the future looks promising. Aspen Pharmacare Holdings is one of the most popular companies on Eulerpool.com.

Aspen Pharmacare Holdings SWOT Analysis

Strengths

Aspen Pharmacare Holdings Ltd has several strengths that contribute to its success in the pharmaceutical industry:

  • Wide product portfolio offering a broad range of therapeutic areas
  • Strong global presence with operations in over 150 countries
  • Well-established brand reputation and recognition
  • Advanced manufacturing capabilities and extensive R&D investments
  • Strong distribution network ensuring efficient delivery of products

Weaknesses

Aspen Pharmacare Holdings Ltd also faces certain weaknesses that may hinder its performance:

  • Heavy reliance on a limited number of key products
  • Increased competition in the global pharmaceutical market
  • Issues related to product quality and regulatory compliance
  • High debt levels may limit future investment opportunities
  • Geographical concentration of revenue streams

Opportunities

Aspen Pharmacare Holdings Ltd can leverage the following opportunities to drive growth and expansion:

  • Emerging markets offer potential for increased sales and market share
  • Growing demand for generics and biosimilars
  • Expansion into new therapeutic areas or healthcare segments
  • Strategic partnerships and acquisitions to enhance product portfolio
  • Focus on research and development for innovative drugs

Threats

Aspen Pharmacare Holdings Ltd faces certain threats that may pose challenges to its operations:

  • Stringent regulatory requirements and pricing pressures
  • Intense competition from both global and local pharmaceutical companies
  • Potential patent expirations and entry of generic competitors
  • Currency fluctuations and economic uncertainties in international markets
  • Increasing healthcare costs and budget constraints
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aspen Pharmacare Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aspen Pharmacare Holdings historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Aspen Pharmacare Holdings shares outstanding

The number of shares was Aspen Pharmacare Holdings in 2023 — This indicates how many shares 444.2 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aspen Pharmacare Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aspen Pharmacare Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aspen Pharmacare Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aspen Pharmacare Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aspen Pharmacare Holdings stock splits

In Aspen Pharmacare Holdings's history, there have been no stock splits.

Aspen Pharmacare Holdings dividend history and estimates

In 2023, Aspen Pharmacare Holdings paid a dividend amounting to 3.42 ZAR. Dividend means that Aspen Pharmacare Holdings distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Aspen Pharmacare Holdings provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Aspen Pharmacare Holdings’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Aspen Pharmacare Holdings's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Aspen Pharmacare Holdings Dividend History

DateAspen Pharmacare Holdings Dividend
2027e4.05 undefined
2026e4.05 undefined
2025e4.06 undefined
20243.79 undefined
20233.42 undefined
20223.26 undefined
20212.62 undefined
20183.15 undefined
20172.87 undefined
20162.48 undefined
20152.16 undefined
20141.88 undefined
20131.57 undefined
20121.57 undefined
20111.05 undefined
20100.7 undefined
20070.69 undefined
20060.61 undefined
20050.47 undefined

Aspen Pharmacare Holdings dividend payout ratio

In 2023, Aspen Pharmacare Holdings had a payout ratio of 23.84%. The payout ratio indicates the percentage of the company's profits that Aspen Pharmacare Holdings distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Aspen Pharmacare Holdings represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Aspen Pharmacare Holdings could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Aspen Pharmacare Holdings's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Aspen Pharmacare Holdings Payout Ratio History

DateAspen Pharmacare Holdings Payout ratio
2027e23.68 %
2026e23.72 %
2025e23.48 %
202423.84 %
202323.84 %
202222.76 %
202124.93 %
202023.84 %
201923.84 %
201823.83 %
201725.68 %
201626.33 %
201518.96 %
201417.12 %
201320.34 %
201224.3 %
201118.52 %
201014.99 %
200923.84 %
200823.84 %
200734.75 %
200634.62 %
200534.18 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Aspen Pharmacare Holdings.

Aspen Pharmacare Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20238.74 7.44  (-14.84 %)2023 Q4
12/31/20217.55 7.77  (2.85 %)2022 Q2
6/30/20207.36 5.6  (-23.94 %)2020 Q4
6/30/20196.53 6.71  (2.67 %)2019 Q4
6/30/20189.14 7.33  (-19.81 %)2018 Q4
12/31/20178.94 8.72  (-2.44 %)2018 Q2
6/30/20178.88 6.59  (-25.77 %)2017 Q4
12/31/20167.23 6.41  (-11.3 %)2017 Q2
6/30/20166.88 8.44  (22.71 %)2016 Q4
12/31/20155.86 4.19  (-28.53 %)2016 Q2
1
2

Eulerpool ESG Scorecard© for the Aspen Pharmacare Holdings stock

Eulerpool World ESG Rating (EESG©)

81/ 100

🌱 Environment

75

👫 Social

99

🏛️ Governance

68

Environment

Scope 1 - Direct Emissions
40,082
Scope 2 - Indirect emissions from purchased energy
111,181
Scope 3 - Indirect emissions within the value chain
32,902.2
Total CO₂ emissions
151,263
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees48
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aspen Pharmacare Holdings shareholders

%
Name
Stocks
Change
Date
18.80010 % Public Investment Corporation (SOC) Limited83,895,438-6,109,1956/30/2024
12.81214 % Saad (Stephen Bradley)57,174,16106/30/2024
6.70003 % Coronation Fund Managers Limited29,898,9066,961,5366/30/2024
4.26311 % Attridge (Michael Gus)19,024,13406/30/2024
4.20002 % Sanlam Investment Management (Pty) Ltd.18,742,5981,785,0096/30/2024
4.10002 % BlackRock Institutional Trust Company, N.A.18,296,346-3,570,0186/30/2024
3.50002 % Old Mutual Investment Group (South Africa) (Pty) Limited15,618,8329,932,5356/30/2024
3.50002 % The Vanguard Group, Inc.15,618,832-1,338,7576/30/2024
3.40002 % Schroder Investment Management Ltd. (SIM)15,172,579446,2526/30/2024
2.50001 % Capital Research Global Investors11,156,3088,970,2396/30/2024
1
2
3
4
5
...
10

Aspen Pharmacare Holdings Executives and Management Board

Mr. Stephen Saad

(59)
Aspen Pharmacare Holdings Group Chief Executive, Executive Director
Compensation 20.78 M

Ms. Lorraine Hill

(60)
Aspen Pharmacare Holdings Group Chief Operations Officer
Compensation 12.75 M

Mr. Sean Capazorio

(58)
Aspen Pharmacare Holdings Group Finance Officer, Executive Director (since 1999)
Compensation 11.46 M

Mr. Reginald Haman

(49)
Aspen Pharmacare Holdings Company Secretary, Group Chief Corporate Services Officer
Compensation 10.88 M

Ms. Zizipho Mmango

(38)
Aspen Pharmacare Holdings Group Chief Strategic Development Officer
Compensation 10.32 M
1
2
3
4

Most common questions regarding Aspen Pharmacare Holdings

What values and corporate philosophy does Aspen Pharmacare Holdings represent?

Aspen Pharmacare Holdings Ltd represents a strong set of values and a clear corporate philosophy. The company aims to provide affordable medicines of high quality to people around the world, thus improving their health and well-being. Aspen Pharmacare values integrity, innovation, and accountability in all aspects of its operations. It focuses on sustainable growth and strategic partnerships to expand its global presence and reach. Aspen Pharmacare is committed to providing access to essential healthcare solutions and ensuring patient safety. With its dedicated workforce and commitment to excellence, Aspen Pharmacare continues to make a positive impact in the pharmaceutical industry.

In which countries and regions is Aspen Pharmacare Holdings primarily present?

Aspen Pharmacare Holdings Ltd is primarily present in various countries and regions worldwide. Some of the key markets where the company operates include South Africa, where it is headquartered, as well as other African countries such as Kenya, Nigeria, and Ethiopia. Additionally, Aspen Pharmacare has a significant presence in Latin American countries including Brazil and Mexico. The company has also expanded its operations into Europe, with a focus on countries like Germany, Spain, Italy, and the United Kingdom. Furthermore, Aspen Pharmacare has a presence in the Asia-Pacific region, including Australia, China, and India.

What significant milestones has the company Aspen Pharmacare Holdings achieved?

Aspen Pharmacare Holdings Ltd, a leading pharmaceutical company, has achieved several significant milestones. Over the years, the company has expanded its global presence and diversified its product portfolio. It has successfully acquired and integrated multiple companies, enhancing its market reach and capabilities. Aspen Pharmacare has also developed and launched innovative medicines, contributing to advancements in healthcare. The company has received numerous industry awards and recognition, further highlighting its commitment to excellence. With a strong focus on research and development, Aspen Pharmacare continues to make substantial contributions to the healthcare industry, delivering high-quality solutions to patients worldwide.

What is the history and background of the company Aspen Pharmacare Holdings?

Aspen Pharmacare Holdings Ltd, commonly known as Aspen, is a leading global pharmaceutical company with a rich history and strong background. Founded in 1850 and headquartered in Durban, South Africa, Aspen has grown into a reputable player in the healthcare industry. The company specializes in the manufacturing and distribution of both branded and generic pharmaceutical products across various therapeutic areas. With a diversified portfolio, Aspen operates in more than 150 countries, serving patients and healthcare professionals worldwide. Over the years, Aspen has made strategic acquisitions and formed partnerships to expand its product offerings and global reach. With a commitment to improving patient lives, Aspen continues to drive innovation and deliver quality healthcare solutions globally.

Who are the main competitors of Aspen Pharmacare Holdings in the market?

The main competitors of Aspen Pharmacare Holdings Ltd in the market are Teva Pharmaceutical Industries Ltd, Mylan N.V., and Sun Pharmaceutical Industries Ltd.

In which industries is Aspen Pharmacare Holdings primarily active?

Aspen Pharmacare Holdings Ltd is primarily active in the pharmaceutical industry.

What is the business model of Aspen Pharmacare Holdings?

The business model of Aspen Pharmacare Holdings Ltd is focused on the manufacturing and marketing of pharmaceutical and healthcare products. Aspen Pharmacare is a leading global supplier of branded and generic pharmaceuticals, as well as infant nutritionals and consumer healthcare products. With a diverse portfolio of products, the company operates across multiple therapeutic areas including anaesthetics, thrombosis, oncology, and respiratory. Aspen Pharmacare also engages in extensive research and development activities to drive innovation within the pharmaceutical industry. Its commitment to quality and affordability ensures the availability of essential medicines to a wide range of markets worldwide.

What is the P/E ratio of Aspen Pharmacare Holdings 2024?

The Aspen Pharmacare Holdings P/E ratio is 17.81.

What is the P/S ratio of Aspen Pharmacare Holdings 2024?

The Aspen Pharmacare Holdings P/S ratio is 1.75.

What is the Quality Investing of Aspen Pharmacare Holdings?

The Quality Investing for Aspen Pharmacare Holdings is 4/10.

What is the revenue of Aspen Pharmacare Holdings 2024?

The Aspen Pharmacare Holdings revenue is 44.71 B ZAR.

How high is the profit of Aspen Pharmacare Holdings 2024?

The Aspen Pharmacare Holdings profit is 4.4 B ZAR.

What is the business model of Aspen Pharmacare Holdings

Aspen Pharmacare Holdings Ltd is an international pharmaceutical company based in South Africa. The company specializes in the production and distribution of pharmaceuticals, biopharmaceuticals, and active ingredients. It is one of the largest manufacturers of generics in Africa. The company's business model is characterized by intensive R&D work and a strong presence in Africa. It produces a wide range of pharmaceutical products for various fields such as psychiatry, oncology, gastroenterology, and pain therapy. Aspen is also a significant provider of veterinary medicines. One of the key aspects of its business model is the production of generics, offering cost-effective alternatives to branded products. This allows Aspen to establish a strong presence and achieve high market penetration in markets with limited investment requirements. The company has expanded its business in Europe and Asia, in addition to its strong presence in Africa. This geographical diversification allows Aspen to reach a broad customer base and minimize risks. Besides its products, Aspen also offers tailored services such as shipping, storage, and logistics management to ensure fast and efficient delivery to customers. The company has also expanded its presence in biopharmaceuticals through the acquisition of ThromboGenics in 2013, making it a leading provider of platelet activating factors. Aspen is committed to social responsibility and has initiated various initiatives to improve access to affordable medical products in Africa. Overall, Aspen Pharmacare Holdings Ltd's business model is based on its wide range of products and services, strategic focus on the African market, and effective implementation of its strategy, which has made it one of the largest and fastest-growing pharmaceutical companies in Africa.

What is the Aspen Pharmacare Holdings dividend?

Aspen Pharmacare Holdings pays a dividend of 3.26 ZAR distributed over payouts per year.

How often does Aspen Pharmacare Holdings pay dividends?

The dividend cannot currently be calculated for Aspen Pharmacare Holdings or the company does not pay out a dividend.

What is the Aspen Pharmacare Holdings ISIN?

The ISIN of Aspen Pharmacare Holdings is ZAE000066692.

What is the Aspen Pharmacare Holdings WKN?

The WKN of Aspen Pharmacare Holdings is A0ET80.

What is the Aspen Pharmacare Holdings ticker?

The ticker of Aspen Pharmacare Holdings is APN.JO.

How much dividend does Aspen Pharmacare Holdings pay?

Over the past 12 months, Aspen Pharmacare Holdings paid a dividend of 3.79 ZAR . This corresponds to a dividend yield of about 2.15 %. For the coming 12 months, Aspen Pharmacare Holdings is expected to pay a dividend of 4.06 ZAR.

What is the dividend yield of Aspen Pharmacare Holdings?

The current dividend yield of Aspen Pharmacare Holdings is 2.15 %.

When does Aspen Pharmacare Holdings pay dividends?

Aspen Pharmacare Holdings pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Aspen Pharmacare Holdings?

Aspen Pharmacare Holdings paid dividends every year for the past 7 years.

What is the dividend of Aspen Pharmacare Holdings?

For the upcoming 12 months, dividends amounting to 4.06 ZAR are expected. This corresponds to a dividend yield of 0.02 %.

In which sector is Aspen Pharmacare Holdings located?

Aspen Pharmacare Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aspen Pharmacare Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aspen Pharmacare Holdings from 9/23/2024 amounting to 0.2 ZAR, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.

When did Aspen Pharmacare Holdings pay the last dividend?

The last dividend was paid out on 9/23/2024.

What was the dividend of Aspen Pharmacare Holdings in the year 2023?

In the year 2023, Aspen Pharmacare Holdings distributed 3.42 ZAR as dividends.

In which currency does Aspen Pharmacare Holdings pay out the dividend?

The dividends of Aspen Pharmacare Holdings are distributed in ZAR.

All fundamentals about Aspen Pharmacare Holdings

Our stock analysis for Aspen Pharmacare Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aspen Pharmacare Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.